Background and objectives There is little information on chronic kidney disease (CKD) stage progression rates and outcomes in liver transplant recipients. Identifying modifiable risk factors may help prevent CKD progression in liver transplant recipients.
Introduction
As improved surgical techniques and intensive care capabilities continue to improve outcomes from liver transplantation, long-term native kidney function in these recipients assumes a more critical role in patient survival. The incidence of ESRD in liver transplant recipients is thought to be Ͼ25% (1-4). Liver transplant recipients are subjected to a variety of stressors that would be expected to influence native renal function at the time of transplant, and during the postoperative period (5) (6) (7) (8) (9) . Furthermore, factors responsible for ESRD in the general public are prevalent in the liver transplant population (10, 11) . These insults may be compounded by the nephrotoxic effects of calcineurin inhibitors (2, (12) (13) (14) (15) (16) (17) .
The actual effect of known risk factors for chronic kidney disease (CKD) such as hypertension, diabetes, hepatitis C, acute renal failure, calcineurin inhibitor nephrotoxicity, and hyperlipidemia on native kidney function in liver transplant recipients remains unknown. It has been shown that renal allograft function within the first year clearly affects long-term allograft survival (18 -22) . We hypothesized that the first year after liver transplantation exerts a considerable stress to the native kidneys, and that events within the first year posttransplant affect the long-term incidence of ESRD in these patients.
We consider the CKD stage at 1 year posttransplant as highly predictive of subsequent ESRD. We therefore analyzed risk factors for CKD stage progression in an effort to identify modifiable risk factors that could prevent stage progression and subsequent ESRD in liver transplant recipients.
Materials and Methods

Patients
After Institutional Review Board approval was obtained, we performed a retrospective review of all adult, primary, deceased-donor, single-organ, primary liver transplants (n ϭ 1151) performed between July 17, 1984 , and December 31, 2007 utilizing the University of Wisconsin prospectively collected transplant database. Limited data from transplants performed before 1994 were obtained with retrospective chart review. Analysis of renal function was per-formed on 972 patients with liver allograft survival Ͼ1 year. Patients who returned to their country of origin, and/or lacked at least three calculated GFR measurements (to establish a stable baseline stage) between postoperative months 11 and 14 despite a functioning liver allograft (n ϭ 242) were excluded. Analysis was based on the remaining 729 patients. Transplant year was divided into eras (1990 -1994, 1995-1999, 2000 -2004, and 2005-2007) .
Kidney Function and Stage Progression
The primary end point in this study was the progression of CKD from one stage to a higher stage group (lower GFR). GFR was calculated using the Modification of Diet in Renal Disease (MDRD) equation (23 If no values were obtained during that block, no progression occurred. Patients who died after the first year posttransplant and did not have CKD progression before their death were censored at the time of death. If they had disease progression before death, they were considered as having an event at the time of their progression. Patients with liver failure were still considered as at risk for subsequent kidney disease progression. Pretransplant kidney function was determined and initially assessed for its potential effect on post-1-year disease progression. Because the assignment of disease progression was based on the kidney function at 1 year posttransplant, we did not believe that the pretransplant kidney function was necessary to include in our final models.
Because of a significant expansion in the variables captured by our database, we were able to analyze a number of additional risk factors for CKD from 1994 onward, and a subset analysis of these patients (n ϭ 680) was conducted to identify other potential risk factors for CKD. Preoperative and intraoperative risk factors, as well as risk factors during the first year posttransplant, were assessed. As this study spanned Ͼ20 years, a number of medical advances have resulted in new diagnoses such as hepatorenal syndrome and novel techniques such as international normalized ratio (INR). Thus, in analysis of these variables, transplants occurring before the origination of these variables were excluded. Physiologic Model for End-stage Liver Disease (MELD) scores were calculated for patients in the pre-MELD era from 1997 onward, when our institution began recording the INR. Hypercholesterolemia was defined as cholesterol levels prompting statin therapy in year 1.
Immunosuppression
Immunosuppression regimens evolved over the 20-year study period as novel agents were introduced. All patients received dexamethasone or methylprednisolone at the time of implantation, and steroids were typically transitioned during the transplant hospitalization to prednisone (20 mg/d). This dose was tapered further over the first postoperative months to a baseline of 5 to 10 mg/d. Approximately one third of patients were weaned completely off steroids at the discretion of their hepatologist by the first year. Two hundred fifteen patients (29%) underwent induction therapy at the discretion of the surgeon including basiliximab (Simulect, Novartis, n ϭ 115), muromonab (OKT3, Ortho Biotech Products, n ϭ 75), alemtuzumab (Campath-1H, ILEX, n ϭ 16), anti-thymocyte globulin (Thymoglobulin, Genzyme, n ϭ 5), and daclizumab (Zenapax, Roche, n ϭ 4). Three hundred sixty-one patients (50%) were maintained on an antimetabolite, either azathioprine (Imuran, GlaxoSmithKline, n ϭ 66) in the earlier years of the study period or a mycophenolate derivative (CellCept, Roche or Myfortic, Novartis) in the later period of the study (n ϭ 295). Seven hundred twenty-four patients (99%) were maintained on a calcineurin inhibitor. During the study period, our group transitioned from a cyclosporinebased maintenance regimen (Neoral, Novartis, n ϭ 161) to a tacrolimus-based regimen (Prograf, Fujisawa, n ϭ 563). Reported drug levels are 12-hour trough levels and were calculated as the mean of all measured calcineurin inhibitor drug levels obtained over the first posttransplant year. Presently, patients receive basiliximab induction if they have preoperative renal dysfunction and are maintained on mycophenolic acid, tacrolimus, and low-dose prednisone postoperatively.
Unexplained elevations in liver function tests were initially evaluated with duplex ultrasonography of the liver allograft to assess vascular patency. If hepatic vascular flow was normal, percutaneous liver biopsy was performed and evaluated using hematoxylin and eosin staining.
Statistical Analyses
Patient and graft survival were estimated by KaplanMeier analysis. Time-dependent variables such as calcineurin drug levels were analyzed over the course of the first year posttransplant. Group comparisons were performed by a log-rank test. Univariate analysis was performed to identify potential risk factors leading to ESRD. Factors found to be significant in univariate analysis were used to construct a multivariate model and assessed with a Cox proportional hazards regression model. Continuous data are presented as mean Ϯ SD. Statistical analysis was performed with SAS software. P values Ͻ0.05 were considered significant.
Results
Demographics
The mean recipient age at the time of transplant was 52.0 Ϯ 10.1 years. Recipients were more commonly men (n ϭ 443, 61%). Caucasian race was most common (n ϭ 696, 96%), with Asian (n ϭ 14) and African American (n ϭ 18) contributing smaller numbers (see Table 1 ).
The vast majority of liver transplants were from donation after brain death donors (n ϭ 690, 95%) compared with donation after cardiac death donors (n ϭ 39, 5%). Mean donor age was 37.1 Ϯ 16.4 years. Donors were more often men (n ϭ 462, 64%) and Caucasian (n ϭ 678, 93%). Donor body mass index (BMI) was 26.2 Ϯ 6.0 kg/m 2 . Mean cold ischemic time was 8.3 Ϯ 2.4 hours.
Indication for Transplantation
The indications for liver transplantation are listed in Figure 1 . The most common primary indications were alcoholic liver disease (n ϭ 232), hepatitis C (n ϭ 153), primary sclerosing cholangitis (n ϭ 87), primary biliary cirrhosis (n ϭ 55), and cryptogenic cirrhosis (n ϭ 40). Less common indications included steatohepatitis (n ϭ 36), autoimmune hepatitis (n ϭ 29), hepatitis B (n ϭ 27), ␣-1 antitrypsin deficiency (n ϭ 21), fulminant failure (n ϭ 14), other inherited metabolic disorders (n ϭ 13), neoplasm (n ϭ 4), other viral hepatitis (n ϭ 3), and other causes (n ϭ 15). Although not always considered the primary indication for transplantation in all cases, 204 patients (28%) were hepatitis C positive.
Patient and Liver Allograft Survival
Kaplan-Meier estimates of patient survival were 91%, 74%, and 64% at 5, 10, and 15 years, respectively. Estimates of liver allograft survival were 89%, 71%, and 60% at the same time points.
Overall CKD Stage Progression
The incidence of ESRD was 2.6%, 7.5%, and 18% at 5, 10, and 20 years. The overall incidence of CKD stage progression (including one-, two-, three-, and four-stage progression) after the first posttransplant year was 28%, 40%, and 53% at 3, 5, and 10 years (Figure 2 Table 2 and Figure 3) . Transplant era was a significant risk factor for stage progression, with CKD stage progression more common in patients from the earliest era (P ϭ 0.01).
Risk Factors for Stage Progression in Liver Transplant Recipients Are Similar to Risk Factors for CKD in the General Population
Univariate analysis revealed that pretransplant diabetes and hypercholesterolemia in the first year posttransplant were risk factors for stage progression after liver transplantation (Table 3) . Additionally, infectious complications during the first year (including total infectious complications as well as urinary tract infections) were predictive of subsequent stage progression. Caucasian race offered protection.
Recipient Factors
Recipient demographic factors such as age, gender, BMI, and indication for liver transplant (including hepatitis C, P ϭ 0.77) were not predictive of subsequent stage progression. Although pretransplant diabetes was a significant risk factor for stage progression, posttransplant diabetes and HgA1c levels at 1 year were nonsignificant (NS) factors. Pre-and posttransplant hypertension were NS risk factors for stage progression.
Immunosuppression
Calcineurin inhibitors were used in the first year posttransplant in 724 patients (99%). There were no significant differences in the rate of stage progression in patients maintained on cyclosporine versus tacrolimus. The mean drug levels over the first year, when grouped as in Table 4 , were not predictive of stage progression. Cessation of either cyclosporine or tacrolimus, or calcineurin inhibitor use altogether was not associated with stage progression.
MELD
Neither transplantation during the MELD era nor the UNOS-listed (UNOS, United Network for Organ Sharing) MELD at transplant was a significant risk factor for CKD stage progression. However, higher physiologic MELD at the time of transplant proved protective. When comparing groups of recipients whose UNOS-listed MELD was Ͼ25 to those whose listed MELD was Ͻ25, a protective effect was noted in the higher MELD group (HR 0.73, CI 0.50 to 1.06, P ϭ 0.10). This approached, but did not reach, statistical significance. The effect of year of transplant was assessed by considering 5-year bins and also by determining if the transplant had been performed during the MELD era. Neither seemed to have much of an effect on disease progression (P ϭ 0.73 for 5-year bins of transplant era, P ϭ 0.31 for the MELD era) and were thus excluded from the final model.
Donor Factors
Donor risk factors such as age, gender, race, BMI, type (donation after brain death versus donation after cardiac death), and cold ischemic time were not predictive of recipient stage progression.
Other Events during the First Year
Hepatorenal syndrome (P ϭ 0.19) at the time of transplant and dialysis during the transplant hospitalization (P ϭ 0.87) were not predictive of stage progression after the first year. Hepatorenal syndrome was associated with the CKD stage at 1 year, however, and patients who experienced hepatorenal syndrome were more likely to have a higher stage at 1 year (P ϭ 0.03). Perioperative factors such those requiring operative reintervention in the first 90 days, and perioperative transfusions, were likewise NS. Cytomegalovirus (CMV) infection was not a significant risk factor.
Multivariate Analysis of Stage Progression
Factors significant in univariate analysis were used to construct a multivariate model. CKD stage at 1 year, pretransplant diabetes, urinary tract infections, and hypercholesterolemia in the first year proved to be independent risk factors for stage progression (Table 5) . 
Discussion
Continued improvements in the immediate and shortterm outcomes of liver transplantation seen in the past 20 years have led to an increasing focus on long-term patient and allograft survival. As patient survival continues to improve, an increasingly large cohort of patients develop ESRD, and physicians can expect this trend to continue in conjunction with improved patient survival. Chronic renal failure is estimated to occur in Ͼ25% of liver transplant recipients at 10 years. We also report that 18% of patients on a calcineurin inhibitor-based maintenance immunosuppressive regimen develop ESRD by 20 years, defined by either initiation of dialysis or renal transplantation. This suggests that close monitoring and management may prevent disease progression in the majority of liver transplant recipients despite the use of calcineurin inhibitors. Although the occurrence of ESRD in recipients of nonrenal transplants is widely known, few guidelines or studies exist to guide management of long-term survivors after liver transplantation in regard to their native renal function. Management of the risk factors for stage progression in recipients with chronic kidney disease may ultimately delay or prevent the onset of ESRD. There was no difference in CKD stage progression between patients maintained on either cyclosporine or tacrolimus. This was found despite the fact that, in general, calcineurin inhibitor use was not minimized or weaned, and levels were maintained within standard therapeutic range in the majority of patients. Typically, calcineurin inhibitors were weaned if patients approached CKD stages 4 and 5.
Risk factors for the development of stage progression in liver transplant recipients were similar to those observed in the general public. Stage progression occurred more commonly in patients with pretransplant diabetes and those with hypercholesterolemia in the first year, and less commonly in Caucasian recipients. It did not seem that posttransplant diabetes or posttransplant hypertension resulted in stage progression. Although difficult to demonstrate, it could be suggested that this reflects appropriate postoperative management of these known risk factors of renal disease.
Consistent with our previous observations in patients with native and transplant CKD, liver transplant recipients with higher baseline (1 year) estimated gfr (eGFR) were more likely to experience stage progression (24) . The CKD stage at 1 year was predictive of subsequent stage progression, with patients at a lower stage (better renal function) at 1 year more likely to experience stage progression. Although the exact mechanisms of progression based on the underlying CKD stage are unknown, it is possible that a higher functional reserve may actually predispose patients to lose their kidney function more rapidly. In univariate analysis, a higher physiologic MELD score was protective from stage progression. This is presumably because patients with a higher MELD tend to have a higher CKD stage and are less likely to experience stage progression. However, this same MELD variable was NS on multivariate analysis, likely because of an interaction between the MELD and the stage at 1 year. As the MELD system is relatively new, patients transplanted within the MELD era or for whom physiologic MELD was calculated (INRs available) have not had as lengthy a follow-up as the pre-MELD recipients. This may introduce a time bias to the analysis.
Interestingly, renal dysfunction at the time of transplant did not affect the likelihood of subsequent stage progression. It is likely that this is because those patients who experienced acute renal failure, or were diagnosed with hepatorenal syndrome, were more likely to have a higher CKD stage at 1 year. Patients in higher CKD stages were less likely to undergo stage progression after the first year. It would seem that the insult to the native kidneys had already occurred and was accounted for in the stage assignment at 1 year.
It is likely that stage progression is multifactorial and results from the summation of a number of insults to the native renal parenchyma. On the basis of this analysis, it seems that the most significant effects were pretransplant diabetes, posttransplant hypercholesterolemia, and postoperative infectious (urinary) complications. As the study cohort was reflective of our patient population, it differed from the national demographic in a number of important ways. The two most notable factors that would be expected to lower the rate of stage progression were the high number of Caucasian recipients and the relatively lower rate of hepatitis C-positive recipients (28%). This rate may be underestimated by the lack of serologic testing for hepatitis C in the early years of the study. Furthermore, the prevalence of hepatitis C in the early years of liver transplantation was lower than it is presently. The low prevalence of hepatitis C in our patient population would be expected to favorably influence CKD progression. Although it would have been important to see if albuminuria influenced CKD progression, these data were not available for the vast majority of patients and we have only recently started to gather this information. Similarly, we used the NKF KDOQI eGFR guidelines but we had no reliable data on proteinuria in individuals with eGFR Ն60. We recognize this as a possible limiting factor and will include proteinuria in our future studies.
Excellent liver allograft and patient survival is now commonplace in the field of liver transplantation. As long-term survival is now expected, rather than the exception, an increasing attention to detail in the long-term management of these patients is necessary. Appropriate management of the risk factors for CKD studied here in liver transplant recipients can lead to an acceptable incidence of CKD stage and progression despite a calcineurin inhibitor-based immunosuppressive regimen. In addition, immunosuppression regimens with calcineurin inhibitors need to be monitored closely in patients with identifiable risk factors for CKD stage progression after liver transplantation.
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